Research ExplorerPublicationsVariants of Toll-like receptor 4 predict cardiac recovery in...

Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy

Standard

Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. / Riad, Alexander; Meyer zu Schwabedissen, Henriette; Weitmann, Kerstin; Herda, Lars R; Dörr, Marcus; Empen, Klaus; Kieback, Arne; Hummel, Astrid; Reinthaler, Marcus; Grube, Marcus; Klingel, Karin; Nauck, Matthias; Kandolf, Reinhard; Hoffmann, Wolfgang; Kroemer, Heyo K; Felix, Stephan B.

In: J BIOL CHEM, Vol. 287, No. 32, 03.08.2012, p. 27236-27243.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Riad, A, Meyer zu Schwabedissen, H, Weitmann, K, Herda, LR, Dörr, M, Empen, K, Kieback, A, Hummel, A, Reinthaler, M, Grube, M, Klingel, K, Nauck, M, Kandolf, R, Hoffmann, W, Kroemer, HK & Felix, SB 2012, 'Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy', J BIOL CHEM, vol. 287, no. 32, pp. 27236-27243. https://doi.org/10.1074/jbc.M112.369728

APA

Riad, A., Meyer zu Schwabedissen, H., Weitmann, K., Herda, L. R., Dörr, M., Empen, K., Kieback, A., Hummel, A., Reinthaler, M., Grube, M., Klingel, K., Nauck, M., Kandolf, R., Hoffmann, W., Kroemer, H. K., & Felix, S. B. (2012). Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J BIOL CHEM, 287(32), 27236-27243. https://doi.org/10.1074/jbc.M112.369728

Vancouver

Riad A, Meyer zu Schwabedissen H, Weitmann K, Herda LR, Dörr M, Empen K et al. Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J BIOL CHEM. 2012 Aug 3;287(32):27236-27243. https://doi.org/10.1074/jbc.M112.369728

Bibtex

@article{fce04a4e10c94f33a5fccda58e594716,
title = "Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy",
abstract = "The clinical course of patients with dilated cardiomyopathy (DCM) varies from cardiac recovery to end stage heart failure. The etiology of this variability is largely unknown. In this study, we investigated the impact of coding polymorphisms of the innate immune protein Toll-like receptor 4 (TLR4) on left ventricular performance in patients with DCM. Two variants of TLR4 (rs4986790, TLR4 c.1187A→G, p.299D→G and rs4986791,TLR4 c.1487C→T, p.T399I) were investigated in 158 patients with DCM. Other reasons for heart failure were excluded by coronary angiography, myocardial biopsy, and echocardiography. Risk factors, age, gender, or treatment did not differ among the groups. At the follow-up evaluation (median 4.0-5.4 months), patients carrying the TLR4 wild type gene displayed cardiac recovery under intense medical heart failure therapy indexed by reduced left ventricular dilation, improved left ventricular ejection fraction, and reduced NT-probrain natriuretic peptide blood level when compared with the initial evaluation. In contrast, patients carrying both the rs4986790 and the rs4986791 variant showed significantly reduced improvement of left ventricular ejection fraction (p = 0.006) and left ventricular dilation (p = 0.015) at the follow-up evaluation when compared with carriers of the wild type gene under the same treatment conditions. In addition, NT-probrain natriuretic peptide level in carriers of both TLR4 variants did not change significantly at the follow up when compared with the first evaluation. Among patients with DCM, the presence of the TLR4 variants rs4986790 and rs4986791 predicts impaired cardiac recovery independently of medical treatment or cardiac risk factors.",
keywords = "Cardiomyopathy, Dilated/physiopathology, Humans, Polymorphism, Genetic, Toll-Like Receptor 4/genetics",
author = "Alexander Riad and {Meyer zu Schwabedissen}, Henriette and Kerstin Weitmann and Herda, {Lars R} and Marcus D{\"o}rr and Klaus Empen and Arne Kieback and Astrid Hummel and Marcus Reinthaler and Marcus Grube and Karin Klingel and Matthias Nauck and Reinhard Kandolf and Wolfgang Hoffmann and Kroemer, {Heyo K} and Felix, {Stephan B}",
year = "2012",
month = aug,
day = "3",
doi = "10.1074/jbc.M112.369728",
language = "English",
volume = "287",
pages = "27236--27243",
journal = "J BIOL CHEM",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "32",

}

RIS

TY - JOUR

T1 - Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy

AU - Riad, Alexander

AU - Meyer zu Schwabedissen, Henriette

AU - Weitmann, Kerstin

AU - Herda, Lars R

AU - Dörr, Marcus

AU - Empen, Klaus

AU - Kieback, Arne

AU - Hummel, Astrid

AU - Reinthaler, Marcus

AU - Grube, Marcus

AU - Klingel, Karin

AU - Nauck, Matthias

AU - Kandolf, Reinhard

AU - Hoffmann, Wolfgang

AU - Kroemer, Heyo K

AU - Felix, Stephan B

PY - 2012/8/3

Y1 - 2012/8/3

N2 - The clinical course of patients with dilated cardiomyopathy (DCM) varies from cardiac recovery to end stage heart failure. The etiology of this variability is largely unknown. In this study, we investigated the impact of coding polymorphisms of the innate immune protein Toll-like receptor 4 (TLR4) on left ventricular performance in patients with DCM. Two variants of TLR4 (rs4986790, TLR4 c.1187A→G, p.299D→G and rs4986791,TLR4 c.1487C→T, p.T399I) were investigated in 158 patients with DCM. Other reasons for heart failure were excluded by coronary angiography, myocardial biopsy, and echocardiography. Risk factors, age, gender, or treatment did not differ among the groups. At the follow-up evaluation (median 4.0-5.4 months), patients carrying the TLR4 wild type gene displayed cardiac recovery under intense medical heart failure therapy indexed by reduced left ventricular dilation, improved left ventricular ejection fraction, and reduced NT-probrain natriuretic peptide blood level when compared with the initial evaluation. In contrast, patients carrying both the rs4986790 and the rs4986791 variant showed significantly reduced improvement of left ventricular ejection fraction (p = 0.006) and left ventricular dilation (p = 0.015) at the follow-up evaluation when compared with carriers of the wild type gene under the same treatment conditions. In addition, NT-probrain natriuretic peptide level in carriers of both TLR4 variants did not change significantly at the follow up when compared with the first evaluation. Among patients with DCM, the presence of the TLR4 variants rs4986790 and rs4986791 predicts impaired cardiac recovery independently of medical treatment or cardiac risk factors.

AB - The clinical course of patients with dilated cardiomyopathy (DCM) varies from cardiac recovery to end stage heart failure. The etiology of this variability is largely unknown. In this study, we investigated the impact of coding polymorphisms of the innate immune protein Toll-like receptor 4 (TLR4) on left ventricular performance in patients with DCM. Two variants of TLR4 (rs4986790, TLR4 c.1187A→G, p.299D→G and rs4986791,TLR4 c.1487C→T, p.T399I) were investigated in 158 patients with DCM. Other reasons for heart failure were excluded by coronary angiography, myocardial biopsy, and echocardiography. Risk factors, age, gender, or treatment did not differ among the groups. At the follow-up evaluation (median 4.0-5.4 months), patients carrying the TLR4 wild type gene displayed cardiac recovery under intense medical heart failure therapy indexed by reduced left ventricular dilation, improved left ventricular ejection fraction, and reduced NT-probrain natriuretic peptide blood level when compared with the initial evaluation. In contrast, patients carrying both the rs4986790 and the rs4986791 variant showed significantly reduced improvement of left ventricular ejection fraction (p = 0.006) and left ventricular dilation (p = 0.015) at the follow-up evaluation when compared with carriers of the wild type gene under the same treatment conditions. In addition, NT-probrain natriuretic peptide level in carriers of both TLR4 variants did not change significantly at the follow up when compared with the first evaluation. Among patients with DCM, the presence of the TLR4 variants rs4986790 and rs4986791 predicts impaired cardiac recovery independently of medical treatment or cardiac risk factors.

KW - Cardiomyopathy, Dilated/physiopathology

KW - Humans

KW - Polymorphism, Genetic

KW - Toll-Like Receptor 4/genetics

U2 - 10.1074/jbc.M112.369728

DO - 10.1074/jbc.M112.369728

M3 - SCORING: Journal article

C2 - 22645142

VL - 287

SP - 27236

EP - 27243

JO - J BIOL CHEM

JF - J BIOL CHEM

SN - 0021-9258

IS - 32

ER -